Business, energy, technology, markets and global industry news from Business News Today

gemcitabine

PharmaDeviceNews gemcitabine
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Pharma & Biotech

How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer

RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.

Read More
Pharma & Biotech

Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial

Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.

Read More